annb0t
Top 20
Biomedical Advanced Research and Development Authority (BARDA) and CSL Seqirus will expand their reserves of MF59® adjuvant to the equivalent of 40 million doses as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS). The multi-year $121.4 million award from BARDA is the fifth avian influenza pandemic preparedness award for CSL Seqirus.
SUMMIT, N.J., Sept. 25, 2024 /PRNewswire/ --Â CSL Seqirus, a business of CSL (ASX: CSL), announced today that through its public-private...
>>> Read more: CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
SUMMIT, N.J., Sept. 25, 2024 /PRNewswire/ --Â CSL Seqirus, a business of CSL (ASX: CSL), announced today that through its public-private...
>>> Read more: CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
